PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) has announced the discontinuation of its VANGARD clinical trial after evaluating interim data and feedback from the FDA regarding the treatment landscape for COVID-19. Although pemziviptadil was well tolerated with no safety concerns, the company concluded that the trial's sample size was insufficient to assess mortality risk adequately. PhaseBio plans to refocus on its ongoing Phase 2b VIP Trial for pulmonary arterial hypertension, with results expected later in 2021.
PhaseBio Pharmaceuticals (Nasdaq: PHAS) has expanded its pivotal Phase 3 REVERSE-IT trial for bentracimab, a novel therapy aimed at reversing the antiplatelet effects of the drug Brilinta, into Canada. This expansion includes the enrollment of the first patients outside the U.S. Bentracimab has shown promise in earlier trials for providing immediate and sustained reversal of ticagrelor's effects, addressing a significant clinical need amid rising cardiovascular issues. The REVERSE-IT trial targets approximately 200 patients globally, focusing on those requiring urgent reversal.